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Introduction: In a recent clinical trial (ACTG 5257), no difference in viral failure (VF) of a first-line cART containing atazanavir/r
(ATV/r) or darunavir/r (DRV/r) was found [1]. For the endpoint of discontinuation due to intolerance, the regimen with DRV/r
was superior to that of ATV/r (49% of the stops of ATV/r were attributed to jaundice or hyperbilirubinemia). These and other
intolerances to ATV/r remain a concern for clinicians.
Methods: Participants in the ICONA Foundation Study who started cART with 2NRTI ATV/r or DRV/r while ART-naı¨ve were
included. Several endpoints were evaluated: confirmed VF200 copies/mL after six months of therapy, discontinuation of DRV/
r or ATV/r for any reasons or because of intolerance/toxicity (as reported by the treating physician) and the combined endpoint
of VF or stop. Survival analysis with KaplanMeier curves and Cox regression model stratified by clinical site was used. Patients’
follow-up accrued from cART initiation to the date of the event or to the date of last available visit/viral load.
Results: 894 patients starting 2NRTIATV/r and 686 2NRTIDRV/r when ART-naı¨ve on average in 2011 (IQR: 20102012) were
studied. Most common NRTIs used were FTC/TDF (84%) and ABC/3TC (12%). Median age was 40 years, 22% females, 44%
heterosexuals. Patients starting ATV/r were more likely to be hepatitis B/C infected (2% and 14% vs 1% and 9%, p0.001), they
started one year earlier (2011 vs 2012, p0.001), were more likely to be enrolled in sites located in the north of Italy (63% vs
54%, p0.04), started cART less promptly after HIV diagnosis (5 vs 2 months, p0.02) and less likely to have started TDF/FTC
(83% vs 85%, p0.02). By two years of cART, 9.8% (95% CI 7.612.0) of those starting ATV/r experienced discontinuation due to
intolerance/toxicity vs 6.5% in DRV/r group (95% CI 4.28.8, p0.04). After controlling for several potential confounders (age,
gender, nation of birth, mode of HIV transmission, hepatitis co-infection status, AIDS diagnosis, nucleoside pair started, baseline
CD4 count and viral load and year of starting cART) the relative hazard (RH) for ATV/r vs DRV/r was 2.01 (95% CI 1.23, 3.28,
p0.005). There were no statistical differences detected for any of the other outcomes.
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Table 1. Relative hazards of reaching the various defined outcomes from fitting a Cox regression model
Outcomes Unadjusted RH (95% CI) p Adjusted RH (95% CI) p
All cause discontinuation
ATV/r vs. DRV/r 1.18 (0.97, 1.43) 0.09 1.16 (0.92, 1.47) 0.20
Discontinuation due to toxicity
ATV/r vs. DRV/r 1.48 (0.98, 2.22) 0.06 2.01 (1.23, 3.28) 0.005
VF200 copies/mL
ATV/r vs. DRV/r 3.49 (1.89, 6.43) B.001 1.63 (0.75, 3.54) 0.22
VF200 copies/mL or discontinuation
ATV/r vs. DRV/r 1.25 (1.02, 1.52) 0.03 1.14 (0.90, 1.45) 0.27
Abstracts of the HIV Drug Therapy Glasgow Congress 2014
Cozzi-Lepri A et al. Journal of the International AIDS Society 2014, 17(Suppl 3):19771
http://www.jiasociety.org/index.php/jias/article/view/19771 | http://dx.doi.org/10.7448/IAS.17.4.19771
1
Conclusions: Although unmeasured confounding cannot be ruled out, our results seem to be consistent with those of the ACTG
5257.When all cause discontinuations were considered, or the composite endpoint of treatment failure, there was no difference
between ATV/r- and DRV/r-based regimens.
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